Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F., de Wit, Ronald, Berry, William R., Horti, Jozsef, Pluzanska, Anna, Chi, Kim N., Oudard, Stephane, Théodore, Christine +4 more·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040720

Cited by (1,006)

Items 101–200 of 1,006

Drug resistance in metastatic castration-resistant prostate cancer
Boštjan Šeruga, Alberto Ocaña, Ian F. Tannock · 2010 · Nature Reviews Clinical Oncology
Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo
Robert D. Loberg, Ying Chi, Matt Craig, Lashon L. Day, Erin Sargent, Chris K. Neeley, Kirk J. Wojno, Linda A. Snyder, Yan Li, Kenneth J. Pienta · 2007 · Cancer Research
Hypoxia‐inducing factors as master regulators of stemness properties and altered metabolism of cancer‐ and metastasis‐initiating cells
Murielle Mimeault, Surinder K. Batra · 2013 · Journal of Cellular and Molecular Medicine
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
Yu Chen, Nicola J. Clegg, Howard I. Scher · 2009 · The Lancet Oncology
Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy
Hailiang Zhang, Lifeng Yang, Yao Zhu, Xudong Yao, Shi‐Lin Zhang, Bo Dai, Yiping Zhu, Yi‐Jun Shen, Guohai Shi, Dingwei Ye · 2010 · The Prostate
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
Lowrance, William, Dreicer, Robert, Jarrard, David F., Scarpato, Kristen R., Kim, Sennett K., Kirkby, Erin, Buckley, David I., Griffin, Jessica C., Cookson, Michael S. · 2023 · Journal of Urology
Docetaxel for treatment of solid tumours: a systematic review of clinical data
Alberto J. Montero, Frank V. Fossella, Gabriel N. Hortobágyi, Vicente Valero · 2005 · The Lancet Oncology
Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators
Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel Peter Petrylak, Gurkamal S. Chatta, Joseph D. Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor Noorali Saleh, David Michael Waterhouse et al. · 2007 · Journal of Clinical Oncology
The Potential of MicroRNAs as Prostate Cancer Biomarkers
Linda Fabris, Yvonne Ceder, Arul M. Chinnaiyan, Guido W Jenster, Karina Dalsgaard Sørensen, Scott A. Tomlins, Tapio Visakorpi, George A. Călin · 2016 · European Urology
Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy
Ethan Basch, David R. Artz, Dorothy Dulko, Kevin S. Scher, Paul J. Sabbatini, Martee Leigh Hensley, Nandita Mitra, John Speakman, Mary S. McCabe, Deborah Schrag · 2005 · Journal of Clinical Oncology
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Navid Sobhani, Dana Rae Tardiel-Cyril, Aram Davtyan, Daniele Generali, Raheleh Roudi, Yong Li · 2021 · Cancers
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
Tito Fojo, Sham Mailankody, Andrew W. Lo · 2014 · JAMA Otolaryngology–Head & Neck Surgery
Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer?
Frederic E. Lecouvet, Jawad El Mouedden, Laurence Collette, Emmanuel Coche, Etienne M. Danse, François Jamar, Jean‐Pascal Machiels, Bruno Vande Berg, Patrick Omoumi, Bertrand F. TOMBAL · 2012 · European Urology
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley, Philip Martin Arlen, Ravi Amrit Madan, Kwong-Yok Tsang, Mary P. Pazdur, Lisa Skarupa, Jacquin L. Jones, Diane J. Poole, Jack P. Higgins, James W. Hodge et al. · 2009 · Cancer Immunology Immunotherapy
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad C, Joan Carles, Silke Gillessen, Axel Heidenreich, Daniel Alexander Heinrich, Jeremy Gratt, Jérémy Lévy, Kurt Miller, Sten F. Nilsson, Oana Petrenciuc et al. · 2016 · The Lancet Oncology
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
Michael Anthony Carducci, Fred Saad C, Per‐Anders Abrahamsson, David Paul Dearnaley, Claude C. Schulman, Scott A. North, Darryl J. Sleep, Jeffrey D. Isaacson, Joel B. Nelson, for the Atrasentan Phase III Study Group Institutions. · 2007 · Cancer
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment
Youmna Sami Kfoury, Ninib Baryawno, Nicolas Sévère, Shenglin Mei, Karin U. Gustafsson, Taghreed Hirz, Thomas Brouse, Elizabeth W. Scadden, Anna A. Igolkina, Konstantinos D. Kokkaliaris et al. · 2021 · Cancer Cell
Using Confirmatory Factor Analysis to Evaluate Construct Validity of the Brief Pain Inventory (BPI)
Thomas Michael Atkinson, Barry D. Rosenfeld, Laura Sit, Tito R. Mendoza, M. Fruscione, Dawn Lavene, Mary Shaw, Yuelin Li, Jennifer L. Hay, Charles S. Cleeland et al. · 2010 · Journal of Pain and Symptom Management
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m 2 ) and the Currently Approved Dose (25 mg/m 2 ) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
Mario A. Eisenberger, Anne Claire Hardy Bessard, Choung‐Soo Kim, Lajos Géczi, Daniel Ford, Loı̈c Mourey, Joan Carles, Phillip Parente, Albert Font Pous, Gabriel Kacsó et al. · 2017 · Journal of Clinical Oncology
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock, Karim S. Fizazi, С. А. Иванов, Camilla Thellenberg Karlsson, Aude Fléchon, Iwona Anna Skoneczna, Francisco Javier Orlandi, Gwénaëlle Gravis, Vsevolod Matveev, Sevil E. Bavbek et al. · 2013 · The Lancet Oncology
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Philip Martin Arlen, James L. Gulley, Catherine Parker, Lisa Skarupa, Mary P. Pazdur, Dennis Panicali, Patricia K. Beetham, Kwong Yok Tsang, Douglas W. Grosenbach, Jarett L. Feldman et al. · 2006 · Clinical Cancer Research
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
Theodoros Karantanos, Christopher P. Evans, Bertrand F. TOMBAL, Timothy C. Thompson, Rodolfo Montironi, William B. Isaacs · 2014 · European Urology
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader, Martin Boegemann, Carsten-H. Ohlmann, Thomas J. Schnoeller, Laura‐Maria Krabbe, Turkan Hajili, Florian Jentzmik, Michael Stöeckle, Mark G. Schrader, Edwin Herrmann et al. · 2013 · European Urology
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Todd Matthew Morgan, Theodore D. Koreckij, Eva Corey · 2009 · Current Cancer Drug Targets
The Role of Chemotherapy at the End of Life: “When Is Enough, Enough?”
Harrington, Sarah Elizabeth, Smith, Thomas J. · 2008 · JAMA
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
Karen A. Autio, Robert Dreicer, Justine Anderson, Jorge Alberto Garcia, Ajjai Shivaram Alva, Lowell L. Hart, Matthew I. Milowsky, Edwin M. Posadas, Charles J. Ryan, Ryon P. Graf et al. · 2018 · JAMA Oncology
Castration-Resistant Prostate Cancer: AUA Guideline
Michael S. Cookson, Bruce J. Roth, Philipp Dahm, Christine A. Engstrom, Stephen J. Freedland, Maha Hussain, Daniel Wei Lin, William Thomas Lowrance, Mohammad Hassan Murad, William K. Oh et al. · 2013 · The Journal of Urology
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
Dana E. Rathkopf, Matthew Raymond Smith, Johann Sebastian De Bono, Christopher J. Logothetis, Neal D. Shore, Paul DE SOUZA, Karim S. Fizazi, Peter Mulders, Paul N. Mainwaring, John Daniel Hainsworth et al. · 2014 · European Urology
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
Andrew J. Armstrong, Elizabeth S. Garrett-Mayer, Yi-Chun Ou Yang, Michael Anthony Carducci, Ian F. Tannock, Ronald de Wit, Mario A. Eisenberger · 2007 · Journal of Clinical Oncology
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
Daniel Peter Petrylak, Donna Pauler Ankerst, Caroline S. Jiang, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Manish Kohli et al. · 2006 · JNCI Journal of the National Cancer Institute
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P. · 2011 · Immunological Reviews
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
William Thomas Lowrance, Rodney Henry Breau, Roger Chou, Brian Francis Chapin, Tony Crispino, Robert Dreicer, David Frazier Jarrard, Adam Stuart Kibel, Todd Matthew Morgan, Alicia Katherine Morgans et al. · 2020 · The Journal of Urology
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren · 2022 · Signal Transduction and Targeted Therapy
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Maoping Cai, Xian‐Lu Song, Xinan Li, Mingkun Chen, Jiading Guo, Dong‐Hua Yang, Zhanghui Chen, Shan‐Chao Zhao · 2023 · Drug Resistance Updates
Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer
Uemura, Motohide, Tamura, Kenji, Chung, Suyoun, Honma, Seijiro, Okuyama, Akihiko, Nakamura, Yusuke, Nakagawa, Hidewaki · 2008 · Cancer Science
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Martin Puhr, Julia Hoefer, Georg Schäfer, Holger H.H. Erb, Su Jung Oh, Helmut Klocker, Isabel Maria Heidegger, Hannes Neuwirt, Zoran Čulig · 2012 · American Journal Of Pathology
The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells
Claudia Tanja Mierke · 2019 · Reports on Progress in Physics
Docetaxel-related side effects and their management
Jackie S. Baker, Jaffer A. Ajani, Florian Scotté, Dorte Winther, Miguel Martín, Matti Aapro, Gϋnter von Minckwitz · 2009 · European Journal of Oncology Nursing
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
Philippe O. Gannon, Alexis O. Poisson, Nathalie Delvoye, Réjean Lapointe, Anne‐Marie Mes‐Masson, Fred Saad C · 2009 · Journal of Immunological Methods
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology
Jean‐Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim et al. · 2010 · British Journal of Urology
Bone metastasis in prostate cancer: emerging therapeutic strategies
Justin Sturge, Matthew P. Caley, Jonathan Waxman · 2011 · Nature Reviews Clinical Oncology
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani‐Mulero, Luigi Portella, Shihua Sun, Matthew S. Sung, Alexandre Matov, Robert L. Vessella, Eva Corey, David M. Nanus, Stephen R. Plymate, Paraskevi Giannakakou · 2014 · Cancer Research
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Kim N. Chi, Anders Bjartell, David Paul Dearnaley, Fred Saad C, Fritz H. Schröder, Cora Sternberg, Bertrand F. TOMBAL, Tapio Visakorpi · 2009 · European Urology
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
Gwénaëlle Gravis, Jean‐Marie Boher, Yu‐Hui Chen, Glenn Liu, Karim S. Fizazi, Michael Anthony Carducci, Stéphane Marie. Oudard, Florence Joly, David M. Jarrard, Michel Soulie et al. · 2018 · European Urology
Pharmaceuticals that contain polycyclic hydrocarbon scaffolds
Tegan P. Stockdale, Craig M. Williams · 2015 · Chemical Society Reviews
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Matthew Robert Sydes, Melissa Ruth Spears, Malcolm David Mason, Noel William Clarke, David Paul Dearnaley, Johann Sebastian De Bono, Gerhardt Attard, S. Chowdhury, William Richard Cross, Silke Gillessen et al. · 2018 · Annals of Oncology
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher, Xiaoyu Jia, Kim Chi, Ronald de Wit, William R. Berry, Peter Albers, Brian S. Henick, David Michael Waterhouse, Dean Ruether, Peter J. Rosen et al. · 2011 · Journal of Clinical Oncology
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew R. Smith, Johann Sebastian De Bono, Cora Nanette Sternberg, Sylvestre Le Moulec, Stéphane Marie. Oudard, Ugo De Giorgi, Michael Krainer, Andries Marinus Bergman, Wolfgang Hoelzer, Ronald de Wit et al. · 2016 · Journal of Clinical Oncology
Nomogram Predicting Prostate Cancer–specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy
John A. Brockman, Shaheen Riadh Alanee, Andrew Julian Vickers, Peter T. Scardino, David P. Wood, Adam Stuart Kibel, Daniel Wei Lin, Fernando J. Bianco, Danny Munther Rabah, Eric A. Klein et al. · 2014 · European Urology
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Janusz Mezynski, Carmel Jo Pezaro, Diletta Bianchini, Andrea Zivi, Shahneen Kaur Sandhu, E. Thompson, J. Hunt, E. Sheridan, Bindumalini Rao Baikady, Ajit Sarvadikar et al. · 2012 · Annals of Oncology
Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer
Bee Ling Tan, Mohd Esa Norhaizan · 2019 · Molecules
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer
Joel B. Nelson, William Love, Joseph L. Chin, Fred Saad C, Claude C. Schulman, Darryl J. Sleep, Jiang X. Qian, Joyce Steinberg, Michael Anthony Carducci, for the Atrasentan Phase 3 Study Group · 2008 · Cancer
Advanced Prostate Cancer: Treatment Advances and Future Directions
Umang Swami, Taylor Ryan McFarland, Roberto Henrique Nussenzveig, Neeraj Agarwal · 2020 · Trends in cancer
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
Jean‐Pierre Droz, Matti Aapro, Lodovico Balducci, Helen J. Boyle, Thomas Van den Broeck, Paul J. Cathcart, Louise Dickinson, Eleni Efstathiou, Mark Emberton, John M. Fitzpatrick et al. · 2014 · The Lancet Oncology
Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
Paul F. Schellhammer, Gerald W. Chodak, James Boyd Whitmore, Robert Brownell Sims, Mark Walter Frohlich, Philip W. Kantoff · 2013 · Urology
Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
Matthew R. Smith, Fred Saad C, Stéphane Marie. Oudard, Neal D. Shore, Karim S. Fizazi, PAUL R. SIEBER, Bertrand F. TOMBAL, Ronaldo Damião, Gavin M. Marx, Kurt Miller et al. · 2013 · Journal of Clinical Oncology
Current treatment strategies for advanced prostate cancer
Kazumasa Komura, Christopher J. Sweeney, Teruo Inamoto, Naokazu Ibuki, Haruhito Azuma, Philip W. Kantoff · 2017 · International Journal of Urology
A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer
Eric Jay Small, Michael Anthony Carducci, James M. Burke, Ron Rodriguez, Lawrence H. Fong, Lynn Van Ummersen, Dechao Yu, Junko Aimi, Dale Genji Ando, Peter K. Working et al. · 2006 · Molecular Therapy
High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
Kristiina Iljin, Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka J. Kohonen, Vidal Fey, Roland C. Grafström, Merja Perälä, Olli Kallioniemi · 2009 · Clinical Cancer Research
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi, Sebastién J. Hotte, Evan Y. Yu, Dongsheng Tu, Bernhard J. Eigl, Ian F. Tannock, Fred Saad C, Scott A. North, Jean Powers, Martin Edwin Gleave et al. · 2010 · Journal of Clinical Oncology
Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer
Eric Jay Small, Natalie Sacks, John J. Nemunaitis, Walter John Urba, Eugene Dula, Arthur S. Centeno, William G. Nelson, Dale Genji Ando, Catherine Howard, Flavia Borellini et al. · 2007 · Clinical Cancer Research
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo, Geralyn Carol Trudel, Fred Saad C, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt B, George Wilding, John McCaffrey, Sergio V Serrano, Vsevolod Borisovich Matveev et al. · 2013 · The Lancet Oncology
Health-related quality of life and cancer clinical trials
David Osoba · 2011 · Therapeutic Advances in Medical Oncology
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Emmanuel S. Antonarakis, Paller · 2011 · Drug Design Development and Therapy
Current Management of Castrate-Resistant Prostate Cancer
Sebastién J. Hotte, Fred Saad C · 2010 · Current Oncology
The Brief Pain Inventory and Its “Pain At Its Worst in the Last 24 Hours” Item: Clinical Trial Endpoint Considerations
Atkinson, Thomas M., Mendoza, Tito R., Sit, Laura, Passik, Steven, Scher, Howard I., Cleeland, Charles, Basch, Ethan · 2010 · Pain Medicine
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
Michelle K. Wilson, Katherine Karakasis, Amit M. Oza · 2014 · The Lancet Oncology
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients—An Analysis of the Medical Literature
Stuart M. Lichtman, Hans P. M. W. Wildiers, Étienne Chatelut, Christopher Steer, Daniel R. Budman, Vicki A. Morrison, Brigitte Tranchand, Iuliana Shapira, Matti Aapro · 2007 · Journal of Clinical Oncology
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Evan Y. Yu, George Wilding, Edwin M. Posadas, Mitchell Eric Gross, Stéphane Culine, Christophe Massard, Michael J. Morris, Gary R. Hudes, Fabio Calabrò, Shinta Cheng et al. · 2009 · Clinical Cancer Research
Incidence of Patients with Bone Metastases at Diagnosis of Solid Tumors in Adults: A Large Population-Based Study
Jin-Feng Huang, Jianfei Shen, Xiao Li, Ramesh Rengan, Nicola Silvestris, Minqi Wang, Lisa Derosa, Xuan-Qi Zheng, Andrea Belli, Xiaolei Zhang et al. · 2019 · Annals of Translational Medicine
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Ravi Amrit Madan, Philip Martin Arlen, Mahsa Mohebtash, James W. Hodge, James L. Gulley · 2009 · Expert Opinion on Investigational Drugs
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Giuseppe Galletti, Benjamin I. Leach, Linda Lam, Scott T. Tagawa · 2017 · Cancer Treatment Reviews
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Hak Choy, Clinton Park, Min Yao · 2008 · Clinical Cancer Research
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression
Wenjian Gan, Xiangpeng Dai, Andrea Lunardi, Zhen Li, Hiroyuki Inuzuka, Pengda Liu, Shoreh Varmeh, Jinfang Zhang, Liang Cheng C, Yin Sun et al. · 2015 · Molecular Cell
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
Jian Zhang, Yuele Lu, Kenneth J. Pienta · 2010 · JNCI Journal of the National Cancer Institute
Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells
Matthieu Flourakis, V’yacheslav Lehen’kyi, Benjamin Beck, Maylis Raphaël, Matthieu Vandenberghe, Fabien Vanden Abeele, Morad M. Roudbaraki, Gilbert Lepage, Brigitte Mauroy, Christoph Romanin et al. · 2010 · Cell Death and Disease
End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
Howard I. Scher, Michael J. Morris, Ethan Basch, Glenn Heller · 2011 · Journal of Clinical Oncology
Survival comparison between glioblastoma multiforme and other incurable cancers
Ben Tran, Mark Andrew Rosenthal · 2010 · Journal of Clinical Neuroscience
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Ricardo M. Attar, Chris H.M. Takimoto, Marco M. Gottardis · 2009 · Clinical Cancer Research
Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device
Brian J. Kirby, Mona Jodari‐Karimi, Matthew S. Loftus, Gunjan Gakhar, Erica D. Pratt, Chantal Chanel‐Vos, Jason P. Gleghorn, Steven M. Santana, He Liu, James Patrick Smith et al. · 2012 · PLoS ONE
Clinical and Correlative Results of SWOG S0354: a Phase II Trial of CNTO328 (siltuximab), a Monoclonal Antibody against Interleukin-6 (IL-6), in Chemotherapy Pre-treated Patients with Castration-Resistant Prostate Cancer (CRPC)
T. Dorff, B. Goldman, J. Pinski, P. Mack, P. Lara, P. Van Veldhuizen, D. Quinn, N. Vogelzang, I. Thompson, M. Hussain · 2010 · Clinical Cancer Research
Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions
Richard Birnie, Steven D. Bryce, Claire Roome, Vincent Dussupt, Alastair Droop, Shona Lang, Paul A. Berry, Catherine F Hyde, John L Lewis, Michael J. Stower et al. · 2008 · Genome biology
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo K. Joensuu, Ray McDermott, Petteri Hervonen, Claes Ginman, Marjaana Luukkaa, Paul Nyandoto, Akseli Hemminki, Sten F. Nilsson et al. · 2013 · The Lancet Oncology
Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer
Celestia S. Higano, John M. Corman, David Carl Smith, Arthur S. Centeno, Christopher P. Steidle, Marc C. Gittleman, Jonathan W. Simons, Natalie Sacks, Junko Aimi, Eric Jay Small · 2008 · Cancer
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Sathekge, Mike M, Lawal, Ismaheel O, Bal, Chandrasekhar, Bruchertseifer, Frank, Ballal, Sajana, Cardaci, Giuseppe, Davis, Cindy, Eiber, Mathias, Hekimsoy, Türkay, Knoesen, Otto et al. · 2024 · The Lancet Oncology
Castration-Resistant Prostate Cancer: AUA Guideline Amendment
Michael S. Cookson, William T. Lowrance, Mohammad Hassan Murad, Adam Stuart Kibel · 2014 · The Journal of Urology
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Роберто Пили, Michael Häggman, Walter Michael Stadler, Jeffrey R. Gingrich, Vasileios J. Assikis, Anders Björk, Örjan Nordle, Göran Forsberg, Michael Anthony Carducci, Andrew J. Armstrong · 2011 · Journal of Clinical Oncology
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
Attard, Gerhardt, Belldegrun, Arie S., De Bono, Johann S. · 2005 · BJU International
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Dominik Berthold, Gregory R. Pond, Martin Roessner, Ronald de Wit, Mario A. Eisenberger, and Ian F. Tannock, on behalf of the TAX-327 investigators · 2008 · Clinical Cancer Research
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong, Elizabeth S. Garrett-Mayer, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger · 2009 · Clinical Cancer Research
Sphingosine Kinase-1 as a Chemotherapy Sensor in Prostate Adenocarcinoma Cell and Mouse Models
Dmitri Pchejetski, Muriel Golzio, Elisabeth Bonhoure, Cyril Calvet, N. Doumerc, Virginie Garcia, Catherine Mazerolles, P. Rischmann, Justin Teissié, Bernard A. Malavaud et al. · 2005 · Cancer Research
Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles
Kenji Tamura, Mutsuo Furihata, Tatsuhiko Tsunoda, Shingo Ashida, Ryo Takata, Wataru Obara, Hiroki Yoshioka, Yataro Daigo, Yasutomo Nasu, Hiromi Kumon et al. · 2007 · Cancer Research
Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Semini Sumanasuriya, Johann Sebastian De Bono · 2017 · Cold Spring Harbor Perspectives in Medicine
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée, Jan Matthijs Moll, Wilma J. Teubel, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske M. van Weerden · 2013 · European Journal of Cancer
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Tetsuya Tanimoto, Akiko Hori, Masahiro Kami · 2010 · New England Journal of Medicine
Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy
Patrick J. Bastian, Ganesh S. Palapattu, Xiaohui S. Lin, Srinivasan Yegnasubramanian, Leslie A. Mangold, Bruce J. Trock, Mario A. Eisenberger, Alan Wayne Partin, William G. Nelson · 2005 · Clinical Cancer Research
Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy
Ping Zhou, Ming‐Hui Chen, David G. McLeod, Peter R. Carroll, Judd W. Moul, Anthony Victor D'Amico · 2005 · Journal of Clinical Oncology
Evolution of androgen receptor targeted therapy for advanced prostate cancer
Yien Ning Sophia Wong, Roberta Ferraldeschi, Gerhardt Attard, Johann Sebastian De Bono · 2014 · Nature Reviews Clinical Oncology
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
Karim S. Fizazi, Johann Sebastian De Bono, Aude Fléchon, Axel Heidenreich, Éric Voog, Nancy B. Davis, Ming Qi, Rajesh R. Bandekar, JESSICA T. VERMEULEN, Mark J. Cornfeld et al. · 2011 · European Journal of Cancer
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan, Shuai Chen, Yuwei Wang, Akira Watahiki, Laura R. Bohrer, Zhen Kui Sun, Yuzhuo Z. Wang, Haojie Huang · 2009 · Cancer Research